Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 1:22 pm Purchase |
2024-12-31 | 13G | Galera Therapeutics, Inc. GRTX |
Ikarian Capital LLC | 7,538,690 9.990% |
7,538,690 (New Position) |
Filing History |
| 2024-05-16 10:26 am Unchanged |
2024-04-16 | 13G | Galera Therapeutics, Inc. GRTX |
Schneid Yair | 10,823,610 19.900% |
0 (Unchanged) |
Filing History |
| 2024-05-16 10:25 am Purchase |
2024-04-16 | 13G | Galera Therapeutics, Inc. GRTX |
Soffer Rochel | 5,928,137 10.899% |
5,928,137 (New Position) |
Filing History |
| 2024-05-01 5:01 pm Purchase |
2024-04-19 | 13G | Galera Therapeutics, Inc. GRTX |
Schneid Yair | 10,823,610 19.900% |
3,712,809 (+52.21%) |
Filing History |
| 2024-04-16 4:39 pm Purchase |
2024-03-22 | 13G | Galera Therapeutics, Inc. GRTX |
ALPHA PHARMA Investments LLC | 2,750,000 5.056% |
2,750,000 (New Position) |
Filing History |
| 2024-04-03 08:08 am Unchanged |
2024-04-01 | 13G | Galera Therapeutics, Inc. GRTX |
Altamont Pharmaceutical Holdings LLC | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2024-02-20 6:57 pm Sale |
2023-02-16 | 13D | Galera Therapeutics, Inc. GRTX |
Sofinnova Venture Partners IX L.P. | 0 0.000% |
-3,083,712 (Position Closed) |
Filing History |
| 2024-02-14 10:14 am Sale |
2023-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
SECTORAL ASSET MANAGEMENT INC | 0 0.000% |
-66,667 (Position Closed) |
Filing History |
| 2024-01-16 6:09 pm Purchase |
2024-01-05 | 13G | Galera Therapeutics, Inc. GRTX |
Schneid Yair | 7,110,801 13.073% |
7,110,801 (New Position) |
Filing History |
| 2024-01-02 08:35 am Purchase |
2024-01-02 | 13G | T2 Biosystems, Inc. TTOO |
GSA CAPITAL PARTNERS LLP | 3,892,561 7.156% |
3,892,561 (New Position) |
Filing History |
| 2023-12-04 4:32 pm Purchase |
2023-12-04 | 13D | Galera Therapeutics, Inc. GRTX |
Blackstone Holdings I/II GP L.L.C. | 2,289,605 4.200% |
15,000 (+0.66%) |
Filing History |
| 2023-11-13 2:24 pm Purchase |
2023-10-31 | 13G | Galera Therapeutics, Inc. GRTX |
Altamont Pharmaceutical Holdings LLC | 5,280,000 12.020% |
5,280,000 (New Position) |
Filing History |
| 2023-06-28 4:19 pm Sale |
2023-06-27 | 13G | Galera Therapeutics, Inc. GRTX |
Novo Holdings A/S | 2,100,000 4.900% |
-359,021 (-14.60%) |
Filing History |
| 2023-02-27 5:43 pm Purchase |
2023-02-17 | 13G | Galera Therapeutics, Inc. GRTX |
Flynn James E | 2,916,401 4.990% |
2,916,401 (New Position) |
Filing History |
| 2023-02-13 3:03 pm Purchase |
2022-12-31 | 13G | eFFECTOR Therapeutics, Inc. EFTR |
SECTORAL ASSET MANAGEMENT INC | 66,667 5.800% |
66,667 (New Position) |
Filing History |
| 2023-02-09 4:49 pm Purchase |
2021-07-19 | 13D | Galera Therapeutics, Inc. GRTX |
Blackstone Holdings I/II GP L.L.C. | 2,274,605 7.800% |
568,197 (+33.30%) |
Filing History |
| 2023-02-03 7:04 pm Sale |
2022-11-09 | 13D | Galera Therapeutics, Inc. GRTX |
Sofinnova Venture Partners IX L.P. | 3,083,712 10.800% |
-1,098 (-0.04%) |
Filing History |
| 2022-02-14 06:26 am Sale |
2021-12-31 | 13G | Galera Therapeutics, Inc. GRTX |
Citadel Advisors LLC | 163,262 0.600% |
-8,471 (-4.93%) |
Filing History |
| 2022-02-11 5:14 pm Purchase |
2022-02-04 | 13G | Galera Therapeutics, Inc. GRTX |
Rosalind Advisors, Inc. | 1,543,783 5.800% |
1,543,783 (New Position) |
Filing History |
| 2022-02-11 4:30 pm Sale |
2021-12-31 | 13G | Galera Therapeutics, Inc. GRTX |
Novartis Bioventures Ltd | 476,085 1.800% |
-1,991,875 (-80.71%) |
Filing History |